Halozyme Therapeutics HALO Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's available-for-sale debt securities - amortized cost?
- Halozyme Therapeutics (HALO) reported available-for-sale debt securities - amortized cost of $8.88M in Q1 2026.
- How has Halozyme Therapeutics's available-for-sale debt securities - amortized cost changed year-over-year?
- Halozyme Therapeutics's available-for-sale debt securities - amortized cost decreased by 98.4% year-over-year, from $571.61M to $8.88M.
- What is the long-term trend for Halozyme Therapeutics's available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's available-for-sale debt securities - amortized cost has grown at a -47.2% compound annual growth rate (CAGR), from $220.22M to $9M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.